{"nctId":"NCT01224171","briefTitle":"Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease","startDateStruct":{"date":"2010-11"},"conditions":["Crohn's Disease"],"count":416,"armGroups":[{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"Vedolizumab","type":"EXPERIMENTAL","interventionNames":["Drug: vedolizumab"]}],"interventions":[{"name":"vedolizumab","otherNames":["Entyvio","MLN0002","MLN02","LDP-02"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age 18 to 80\n* Diagnosis of moderately to severely active Crohn's disease\n* Crohn's Disease involvement of the ileum and/or colon\n* Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance of at least one conventional therapy as defined by the protocol\n* May be receiving a therapeutic dose of conventional therapies for inflammatory bowel disease (IBD) as defined by the protocol\n\nExclusion Criteria\n\n* Evidence of abdominal abscess at the initial screening visit\n* Extensive colonic resection, subtotal or total colectomy\n* History of \\>3 small bowel resections or diagnosis of short bowel syndrome\n* Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine\n* Have received non permitted therapies within either 30 or 60 days, depending on the medication, as stated in the protocol\n* Chronic hepatitis B or C infection; human immunodeficiency virus (HIV) infection\n* Active or latent tuberculosis","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation","description":"Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points.\n\nThe CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:\n\n* Number of liquid or soft stools each day for 7 days;\n* Abdominal pain (graded from 0-3 on severity) each day for 7 days;\n* General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days;\n* Presence of complications;\n* Taking Lomotil or opiates for diarrhea;\n* Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite);\n* Hematocrit of \\< 0.47 in men and \\< 0.42 in women;\n* Percentage deviation from standard weight.\n\nThe total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity.\n\nAll participants who prematurely discontinued for any reason were considered as not achieving clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"15.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Clinical Remission at Week 6 in the Overall Population","description":"Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points.\n\nThe CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:\n\n* Number of liquid or soft stools each day for 7 days;\n* Abdominal pain (graded from 0-3 on severity) each day for 7 days;\n* General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days;\n* Presence of complications;\n* Taking Lomotil or opiates for diarrhea;\n* Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite);\n* Hematocrit of \\< 0.47 in men and \\< 0.42 in women;\n* Percentage deviation from standard weight.\n\nThe total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity.\n\nAll participants who prematurely discontinued for any reason were considered as not achieving clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"19.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Clinical Remission at Week 10 in the TNFα Antagonist Failure Subpopulation","description":"Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points.\n\nThe CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:\n\n* Number of liquid or soft stools each day for 7 days;\n* Abdominal pain (graded from 0-3 on severity) each day for 7 days;\n* General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days;\n* Presence of complications;\n* Taking Lomotil or opiates for diarrhea;\n* Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite);\n* Hematocrit of \\< 0.47 in men and \\< 0.42 in women;\n* Percentage deviation from standard weight.\n\nThe total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity.\n\nAll participants who prematurely discontinued for any reason were considered as not achieving clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"26.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants in Clinical Remission at Week 10 in the Overall Population","description":"Clinical remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points.\n\nThe CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:\n\n* Number of liquid or soft stools each day for 7 days;\n* Abdominal pain (graded from 0-3 on severity) each day for 7 days;\n* General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days;\n* Presence of complications;\n* Taking Lomotil or opiates for diarrhea;\n* Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite);\n* Hematocrit of \\< 0.47 in men and \\< 0.42 in women;\n* Percentage deviation from standard weight.\n\nThe total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity.\n\nAll participants who prematurely discontinued for any reason were considered as not achieving clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.0","spread":null},{"groupId":"OG001","value":"28.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Clinical Remission in the TNFα Antagonist Failure Population","description":"Sustained clinical remission is defined as a CDAI score ≤ 150 points at both Week 6 and Week 10. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:\n\n* Number of liquid or soft stools each day for 7 days;\n* Abdominal pain (graded from 0-3 on severity) each day for 7 days;\n* General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days;\n* Presence of complications;\n* Taking Lomotil or opiates for diarrhea;\n* Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite);\n* Hematocrit of \\< 0.47 in men and \\< 0.42 in women;\n* Percentage deviation from standard weight.\n\nThe total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity.\n\nAll participants who prematurely discontinued for any reason were considered as not achieving sustained clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":null},{"groupId":"OG001","value":"12.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Clinical Remission in the Overall Population","description":"Sustained clinical remission is defined as a CDAI score ≤ 150 points at both Week 6 and Week 10. The CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:\n\n* Number of liquid or soft stools each day for 7 days;\n* Abdominal pain (graded from 0-3 on severity) each day for 7 days;\n* General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days;\n* Presence of complications;\n* Taking Lomotil or opiates for diarrhea;\n* Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite);\n* Hematocrit of \\< 0.47 in men and \\< 0.42 in women;\n* Percentage deviation from standard weight.\n\nThe total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity.\n\nAll participants who prematurely discontinued for any reason were considered as not achieving sustained clinical remission.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":null},{"groupId":"OG001","value":"15.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Enhanced Clinical Response at Week 6 in the TNFα Antagonist Failure Subpopulation","description":"Enhanced clinical response is defined as a ≥ 100-point decrease in CDAI score from Baseline.\n\nThe CDAI is used to quantify the symptoms of patients with Crohn's disease and consists of eight factors, each summed after adjustment with a weighting factor. The components of the CDAI are:\n\n* Number of liquid or soft stools each day for 7 days;\n* Abdominal pain (graded from 0-3 on severity) each day for 7 days;\n* General well-being, subjectively assessed from 0 (well) to 4 (terrible) each day for 7 days;\n* Presence of complications;\n* Taking Lomotil or opiates for diarrhea;\n* Presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite);\n* Hematocrit of \\< 0.47 in men and \\< 0.42 in women;\n* Percent deviation from standard weight.\n\nThe total score ranges from 0 to approximately 600 and with higher scores indicating greater disease activity.\n\nAll participants who prematurely discontinued for any reason were considered as not achieving enhanced clinical response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":null},{"groupId":"OG001","value":"39.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs)","description":"An AE was defined as any untoward medical occurrence in a patient administered a pharmaceutical product, which did not necessarily have a causal relationship with the treatment. A serious adverse event (SAE) was any AE, occurring at any dose and regardless of causality that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was an important medical event based upon appropriate medical judgment that may have jeopardized the patient and may have required medical or surgical intervention to prevent 1 of the outcomes listed above, or any diagnosis of progressive multifocal leukoencephalopathy (PML).\n\nRelationship to study drug administration was determined by the investigator responding yes or no to the question: Is there a reasonable possibility that the AE is associated with the study drug?","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"117","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":16,"n":207},"commonTop":["Headache","Pyrexia","Nausea"]}}}